Cryoport公司2025年季度报告

Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” AcceleratedfilerSmallerreportingcompa Indicate by check mark whether the Registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). As of April 25, 2025, there were50,137,218shares of the registrant's common stock outstanding. TABLE OF CONTENTS Cryoport,Inc. and SubsidiariesCondensed Consolidated Balance Sheets(in thousands, except share data) Cryoport,Inc. and SubsidiariesCondensed Consolidated Statements of Operations Cryoport,Inc. and SubsidiariesCondensed Consolidated Statements of Comprehensive Loss Cryoport,Inc. and SubsidiariesCondensed Consolidated Statements of Stockholders’ Equity Cryoport,Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows Table of Contents Cryoport,Inc. and SubsidiariesNotesto Condensed Consolidated Financial StatementsFor the Three Months Ended March 31, 2025 and 2024(Unaudited) Note1. Management’s Representation and Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared byCryoport,Inc. (the “Company”, “Cryoport”, “our” or “we”) in accordance with accounting principles generallyaccepted in the United States of America (“U.S. GAAP”) for interim financial information, and pursuant to theinstructions to Form10-Q and Article10 of Regulation S-X promulgated by the Securities and ExchangeCommission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. Operating results for the three months ended March31,2025 are not necessarily indicative of the resultsthat may be expected for the year ending December31,2025. The unaudited condensed consolidated financial The Company has evaluated subsequent events through the date of this filing and determined that nosubsequent events have occurred that would require recognition in the unaudited condensed consolidated Note2.Nature of the Business Cryoport is a leading global provider of temperature-controlled supply chain solutions for the LifeSciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contractmanufacturers(CDMOs),contract research organizations(CROs),developers,and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across thetemperature-controlled supply chain for the Life Sciences. Our integrated supply chain platform includes theCryoportal®Logistics Management Platform,advanced temperature-controlled packaging,informatics, On March 31, 2025, we entered into a definitive agreement (the “Sale and Purchase Agreement”) withDHL Supply Chain International Holding B.V. (“DHL”), pursuant to which the Company would divest itsCRYOPDP specialty courier business to DHL, an operating segment within its Life Sciences Services reportablesegment. The purchase price is based on a total enterprise value of $195million, comprised of a cash payment ofapproximately $138million, subject to typical adjustments for customary items, and the repayment of outstandingintercompany loans owed by CRYOPDP to the Company, estimated to be approximately $67 million, acomponent of net debt of approximately $57million. The Sale and Purchase Agreement provides that at closing,and as a condition to the closing obligations of the parties, the parties and/or their affiliates will enter into certain The transaction is subject to customary closing conditions, including regulatory approval under relevantgovernment antitrust and foreign direct investment laws, and is expected to close in the second or third quarter of2025. The transaction represents a strategic shift that has a major effect on the Company’s operations andfinancial results, and as a result, the results of the CRYOPDP business were classified as discontinued operationsin our condensed consolidated statements of operations and excluded from both continuing operations and Table of Contents The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Marketexchange under the ticker symbol “CYRX.” Note3. Summary of Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the threemonths ended March31,2025, except for those related to discontinued operations, as compared to the significant Discontinued Operations We review the presentation of planned business dispositions in the condensed consolidated financialstatements based on